BCR and chronic myelogenous leukemia, BCR-ABL1 positive: One such example is Imatinib mesylate (Gleevec), a tyrosine kinase inhibitor which was developed to inhibit tyrosine kinase BCR-ABL in chronic myeloid leukemia (CML).